Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity
详细信息 查看全文
- 作者：Natalia J. Martinez ; Anton Simeonov ; asimeono@mail.nih.gov" class="auth_mail" title="E-mail the corresponding author
- 刊名：Drug Discovery Today: Technologies
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：18
- 期：Complete
- 页码：9-17
- 全文大小：789 K
文摘
Histone methylation is a prevalent and dynamic chromatin modification, executed by the action of histone methyltransferases (HMTs) and demethylases (HDMs). Aberrant activity of many of these enzymes is associated with human disease, hence, there is a growing interest in identifying corresponding small molecule inhibitors with therapeutic potential. To date, most of the technologies supporting the identification of these inhibitors constitute in vitro biochemical assays which, although robust and sensitive, do not study HMTs and HDMs in their native cellular state nor provide information of inhibitor's cell permeability and toxicity. The evident need for complementary cellular approaches has recently propelled the development of cell-based assays that enable screening of HMT and HDM enzymes in a more relevant environment. Here, we highlight current cellular methodologies for HMT and HDM drug discovery support. We anticipate that implementation of these cell-based assays will positively impact the discovery of pharmacologically potent HMT and HDM inhibitors.